Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Genetic Predictors of Variability in the Drug-Drug Interaction Between Darunavir/Ritonavir and Pravastatin
This study is currently recruiting participants.
Study NCT00630734 Information provided by University of Colorado at Denver and Health Sciences Center
First Received: February 28, 2008 Last Updated: March 6, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Hyperlipidemia
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Hyperlipidemias
Infection
More general conditions related to this trial
Dyslipidemias
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Lipid Metabolism Disorders
Metabolic Diseases
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Pravastatin, darunavir, ritonavir
Additional drug interventions recognized in this trial
Darunavir
Pravastatin
Ritonavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Anticholesteremic Agents
Antilipemic Agents
Antimetabolites
Antiviral Agents
Enzyme Inhibitors
HIV Protease Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
University of Colorado at Denver and Health Sciences Center
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Back to top of Main Content
